Otsuka Holdings Co Ltd - Company Profile
Powered by 
All the data and insights you need on Otsuka Holdings Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Otsuka Holdings Co Ltd Strategy Report
- Understand Otsuka Holdings Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Otsuka Holdings Co Ltd (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions, and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices, and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.
Headquarters
Japan
Address
Shinagawa Grand Central Tower, 2-16-4, Konan, Minato-Ku, Tokyo, 108-8241
Website
www.otsuka.com
Telephone
81 3 67171410
No of Employees
33,482
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4578 (TYO)
Revenue (2022)
$12.8B
16%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
6.8%
(2022 vs 2021)
Market Cap*
$21.4B
Net Profit Margin (2022)
XYZ
-7.9%
(2022 vs 2021)
* As of and is in US$
Otsuka Holdings Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Pharmaceuticals: | Transportation | Abilify |
| Anti-psychotic | Warehousing | Sprycel |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In August, Taiho Pharmaceutical announced its plans to launch Lytgobi (futibatinib). |
| 2023 | Regulatory Approval | In May, Otsuka Pharmaceutical and H Lundbeck received approval for the supplemental new drug application from the US Food and Drug Administration for Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzheimer’s disease. |
| 2023 | Contracts/Agreements | In February, the company finalized a collaborative agreement with Naruto City and Toyota Tsusho Corporation to contribute to realization of a sustainable society. |
Competitor Comparison
| Key Parameters | Otsuka Holdings Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Mitsubishi Tanabe Pharma Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Minato-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 33,482 | 14,484 | 17,435 | 7,771 | 6,697 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ichiro Otsuka | Chairman; Representative Director | Executive Board | 2015 | 58 |
| Tatsuo Higuchi | Director; President; Chief Executive Officer | Executive Board | 2008 | 73 |
| Yuko Makino | Chief Financial Officer; Director | Executive Board | 2019 | 62 |
| Makoto Inoue | Director; President | Executive Board | 2020 | 65 |
| Yoshiro Matsuo | Director; Executive Deputy President | Executive Board | 2022 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward